Table 6.
Multivariate analysis of prognostic factors for PFS and OS
| Factors | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| ECOG PS (2–4) | 2.185 (0.778–6.131) | 0.138 | 3.945 (0.851–18.295) | 0.080 |
| Stage Ⅲ/Ⅳ | 1.201 (0.351–4.112) | 0.770 | 1.581 (0.159–15.697) | 0.696 |
| Treatment (SMILE) | 3.085 (1.334–7.136) | 0.008* | 2.860 (1.050–7.787) | 0.040* |
| Pre‐treatment EBV‐DNA positivity | 1.101 (0.376–3.221) | 0.861 | 1.785 (0.407–7.817) | 0.442 |
| Post‐treatment EBV‐DNA positivity | 5.233 (1.958–13.984) | 0.001* | 4.197 (1.285–13.714) | 0.018* |
CI, confidence interval; EBV, Epstein‐Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; SMILE, methotrexate, dexamethasone, ifosfamide, L‐asparaginase, and etoposide.
*
P < 0.05.